For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com  Inclusion Criteria:  Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at Screening Meets the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at Screening Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and Day 1 Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening  Exclusion Criteria:  Nonplaque psoriasis at Screening or Day 1 Other autoimmune condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease) Active fibromyalgia Received an approved or investigational biologic therapy for the treatment of PsA or PsO  Other protocol-defined inclusion/exclusion criteria apply